A Systematic Review on Retinal Biomarkers to Diagnose Dementia from OCT/OCTA Images
- PMID: 38025800
- PMCID: PMC10657718
- DOI: 10.3233/ADR-230042
A Systematic Review on Retinal Biomarkers to Diagnose Dementia from OCT/OCTA Images
Abstract
Background: Traditional methods for diagnosing dementia are costly, time-consuming, and somewhat invasive. Since the retina shares significant anatomical similarities with the brain, retinal abnormalities detected via optical coherence tomography (OCT) and OCT angiography (OCTA) have been studied as a potential non-invasive diagnostic tool for neurodegenerative disorders; however, the most effective retinal changes remain a mystery to be unraveled in this review.
Objective: This study aims to explore the relationship between retinal abnormalities in OCT/OCTA images and cognitive decline as well as evaluating biomarkers' effectiveness in detecting neurodegenerative diseases.
Methods: A systematic search was conducted on PubMed, Web of Science, and Scopus until December 2022, resulted in 64 papers using agreed search keywords, and inclusion/exclusion criteria.
Results: The superior peripapillary retinal nerve fiber layer (pRNFL) is a trustworthy biomarker to identify most Alzheimer's disease (AD) cases; however, it is inefficient when dealing with mild AD and mild cognitive impairment (MCI). The global pRNFL (pRNFL-G) is another reliable biomarker to discriminate frontotemporal dementia from mild AD and healthy controls (HCs), moderate AD and MCI from HCs, as well as identifing pathological Aβ42/tau in cognitively healthy individuals. Conversely, pRNFL-G fails to realize mild AD and the progression of AD. The average pRNFL thickness variation is considered a viable biomarker to monitor the progression of AD. Finally, the superior and average pRNFL thicknesses are considered consistent for advanced AD but not for early/mild AD.
Conclusions: Retinal changes may indicate dementia, but further research is needed to confirm the most effective biomarkers for early and mild AD.
Keywords: Alzheimer’s disease; dementia; mild cognitive impairment; neurodegenerative disorders; optical coherence tomography; optical coherence tomography angiography; retinal biomarkers.
© 2023 – The authors. Published by IOS Press.
Conflict of interest statement
The authors have no conflict of interest to report.
Figures
References
-
- World Health Organization, Dementia, WHO, https://www.who.int/news-room/fact-sheets/detail/dementia, Accessed December 16, 2022.
-
- NHS-UK, About dementia - dementia guide, NHS, https://www.nhs.uk/conditions/dementia/about/?tabname=about-dementia, Accessed April 6, 2022.
-
- NIA-scientists, How biomarkers help diagnose dementia,National Institute on Aging, https://www.nia.nih.gov/health/how-biomarkers-helpdiagnose-dementia, Accessed April 6, 2022.
-
- NHS-UK, MRI scan, https://www.nhs.uk/conditions/mriscan/, Accessed December 16, 2022.
-
- Mounsey A, Zeitler MR (2018) Cerebrospinal fluid biomarkers for detection of Alzheimer disease in patients with mild cognitive impairment. Am Fam Physician 97, 714–715. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
